ClinicalTrials.gg
RecruitingNCT07068789Updated Jul 16, 2025

Revascularization of Single Vesrus Multiple Infrapopliteal Vessels in Chronic Limb Threatening Ischemia

An interventional study of balloon angioplasty in Chronic Limb Threatening Ischemia and Infrapopliteal Arterial Occlusive Disease, sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-16.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Chronic Limb-Threatening Ischemia with a site in Egypt — 2 open to participants now, 5 under way, none of them phase 3. Chronic Limb-Threatening Ischemia · Egypt.

Started
2025
with 2 others
No phase
4 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
Sohag University

Among the 10 studies in Chronic Limb-Threatening Ischemia with a site in Egypt, this one is one of 3 that started in 2025, is one of 4 with no phase, and was the 7th registered.

Chronic Limb-Threatening Ischemia

359 studies on the registry are indexed under Chronic Limb-Threatening Ischemia; 73 are open to participants now.

Browse Chronic Limb-Threatening Ischemia studies →

Open to participants now

2 of the 10 studies in Chronic Limb-Threatening Ischemia with a site in Egypt are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 51 Chronic Limb-Threatening Ischemia studies recruiting now, 35 (69%) set no upper age limit and 2 (4%) stop at 75 or younger; 3 take children under 18; 6 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Chronic Limb-Threatening Ischemia with a site in Egypt, or all of them as a file.
02

Study summary

This interventional prospective study aims to assess the effectiveness of single vessel versus multiple vessel infrapopliteal angioplasty in patients with chronic threatening limb ischemia . The study compares limb salvage rates and clinical outcomes across two groups over a defined follow up period

03

Conditions studied

  • Chronic Limb Threatening Ischemia
  • Infrapopliteal Arterial Occlusive Disease

Keywords

  • chronic limb threatening ischemia
  • infrapopliteal arteries angioplasty
  • limb salvage
  • endovascular revascularization
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: 1. patients aged 40 years or older 2. patients with Rutherford category "4" and "5" 3. patients with angiographic evidence of infrapopliteal vessel occlusive disease -

Exclusion Criteria:

  1. patients who refuse to participate in the study
  2. patients with isolated proximal arterial disease (e.g SFA or popliteal ) without infrapopliteal involvement
  3. patients who develop acute thrombosis , flow limiting dissection or perforation in the infrapopliteal arteries during intervention -
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    three vessel revascularization

    patients in this group will undergo will receive angioplasty of all three infrapopliteal arteries

    Procedure: balloon angioplasty

  • Experimental
    two vessel revascularization

    patients in this group will undergo will receive angioplasty of two infrapopliteal arteries

    Procedure: balloon angioplasty

  • Experimental
    single vessel revascularization

    patients in this group will undergo will receive angioplasty of only one infrapopliteal artery

    Procedure: balloon angioplasty

Interventions

  • Procedureballoon angioplasty

    endovascular angioplasty of infrapopliteal arteries performed using standard balloon catheters under fluroscopic guidance to restore blood flow to the ischemic area

06

What researchers measure

Primary outcomes

  1. limb salvage rate

    percentage of patients who remain free from major lower limb amputation during the period of follow up after angioplasty

    Time frame: 6 months ( with optional follow up at 12 months )

  2. limb salvage rate

    percentage of patients who avoid major amputation during the period of follow up following angioplasty procedure

    Time frame: 6 months ( with optional follow up at 12 months )

07

Study locations

1 of 1 sites recruiting
  • Faculty of Medicine of Sohag
    Sohag, Sohag Governorate 82511, Egypt
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — not applicable data will be used internally for academic purpose only

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Aug 2025, 2 months after the start.

Of 72 interventional studies with no phase under Chronic Limb-Threatening Ischemia, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 85. This study's planned 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 7, 2025
First posted
Jul 16, 2025
StartActual
Jun 25, 2025
Primary completionEst.
Aug 25, 2025
CompletionEst.
Sep 25, 2025
Last update
Jul 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07068789
Lead sponsor
Sohag University
Responsible party
Mahmoud Abdelrahman Hafez (Mahmoud Abdelrahman Hafez, Sohag University) — Principal investigator
First posted
Jul 16, 2025
Start date
Jun 25, 2025
Primary completion
Aug 25, 2025 (estimated)
Completion
Sep 25, 2025 (estimated)
Last update
Jul 16, 2025

Study contacts

Mahmoud Abdelrahman hafez, Master's student
Contact
mahmoud.abdelrahmaan@med.sohag.edu.eg
+0201060150246
Mahmoud El-saedy, MB BCh ( candidate )
Contact
elsaedymahmoud13@gmail.com
+0201120908609

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion